Physician profile
Hatim Lukman
NPI 1801901707
$3,400.42
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,363 · 2020: $197 · 2021: $571 · 2022: $160 · 2024: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $108.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,436.60 | 2019 | |
| Novo Nordisk INC | $1,012.30 | 2019-2024 | Wegovy |
| Abbvie INC. | $221.33 | 2019-2022 | |
| Astellas Pharma US INC | $195.74 | 2019 | |
| Pfizer INC. | $113.39 | 2019-2020 | |
| Therapeuticsmd, INC. | $104.60 | 2019-2020 | |
| Roche Diagnostics Corporation | $37.91 | 2019 | |
| Allergan, INC. | $32.81 | 2019 | |
| Amgen INC. | $32.02 | 2019 | |
| Organon LLC | $30.78 | 2021 | |
| Hologic Sales and Service, LLC | $26.92 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.58 | 2019 | |
| Duchesnay USA Incorporated | $24.99 | 2019 | |
| Exeltis, USA INC. | $18.74 | 2021 | |
| Mayne Pharma Commercial LLC | $18.41 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $14.62 | 2020 | |
| Kvk-Tech, INC. | $14.47 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.13 | 2019 | |
| Lupin INC. | $13.99 | 2019 | |
| Ethicon US, LLC | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hatim Lukman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.